Imago is committed to developing true differentiating therapies, by focusing on eradicating stem cells responsible for myeloid malignancies. Our lead preclinical program is currently in IND-qualifying studies as a potential candidate for myelofibrosis (MF), acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), and other diseases.
Myeloid malignancies, blood cell cancers arising in the bone marrow, have long been associated with disruptions of epigenetic regulation. There are many clinical versions of myeloid diseases, all of which can evolve into life-threatening phases. As with other cancers, several different types of agents may be needed to bring myeloid diseases under control.
Imago BioSciences is currently conducting clinical studies of its lead molecule IMG-7289 in myeloid cancers and related neoplastic diseases. The first-in-patient study of IMG-7289 was initiated in late 2016 in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome. The multiple-ascending dose Phase 1 portion of that study was concluded in 2017. The Phase 2 study of IMG-7289 in combination with all-trans retinoic acid (ATRA) is currently enrolling patients.
A Phase 2a study of IMG-7289 in patients with high risk myelofibrosis is currently enrolling.